Vitruvias Therapeutics is recalling one lot of thyroid medication distributed nationwide after testing found the tablets could be more potent than intended, according to a recall notice published by the U.S. Food and Drug Administration (FDA).

The Auburn, Alabama-based company voluntarily recalled Lot 504950 of Thyroid Tablets, USP 30 mg at the consumer level because of the potential for the medication to be “superpotent.” 

The FDA published the company announcement Monday.

Taking superpotent thyroid tablets can cause hyperthyroidism, or an overactive thyroid, with symptoms that can include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate and heart rhythm disturbances, according to the company.

DOG FOOD RECALLED ACROSS US AND CANADA AFTER COMPLAINTS OF METAL CONTAMINATION

Vitruvias Therapeutics is recalling one lot of Thyroid Tablets, USP 30 mg, after testing confirmed the product could be more potent than intended. (FDA / Unknown)

Elderly patients, pregnant women and infants face greater risks from excessive thyroid hormone levels, particularly with extended use, the company said. 

Excess thyroid hormone has been associated with cardiac problems in elderly patients, while overtreatment during pregnancy has been associated with premature delivery and low birth weight. In infants, overtreatment may negatively affect growth and development.

Vitruvias Therapeutics said it has not received any reports of adverse events known to be connected to the recall.

The recalled product carries NDC 69680-166-00 and an expiration date of Sept. 30, 2026. The company released 3,655 units and reported 1,955 units sold.

TESLA RECALLS NEARLY 3M VEHICLES OVER DOORS THAT MAY BE DIFFICULT TO OPEN AFTER CRASHES

The recall notice was posted by the FDA. (Sarah Silbiger/Getty Images / Getty Images)

The affected lot was distributed nationwide to the company’s direct accounts between Jan. 31, 2025, and Sept. 30, 2025.

Thyroid, USP is derived from porcine thyroid glands and contains levothyroxine and liothyronine. The medication is used to treat hypothyroidism, or an underactive thyroid.

Vitruvias Therapeutics is notifying wholesalers to stop distributing the recalled product and arranging for its destruction.

E COLI AND SALMONELLA OUTBREAK LINKED TO ALFALFA SPROUTS SICKENS DOZENS ACROSS MULTIPLE STATES

A pharmacist pulls a drug from a shelf inside a pharmacy in Provo, Utah. (George Frey/Bloomberg via Getty Images, File / Getty Images)

Patients currently taking tablets from the affected lot should not stop taking the medication without first contacting their healthcare provider for guidance or a replacement prescription, the company said.

A representative for Vitruvias Therapeutics did not immediately respond to FOX Business’ request for additional information.

CLICK HERE TO GET FOX BUSINESS ON THE GO

Consumers with questions can contact Vitruvias Therapeutics at safety@vitruvias.com or at 256-239-9373. 

Anyone who has experienced problems that may be connected to the medication should contact a physician or healthcare provider.

The recall is being conducted with the knowledge of the FDA.

Brokerages remain constructive on select stocks, with Varun Beverages, Cyient, and Nykaa emerging as key picks despite differing growth trajectories.Morgan Stanley retained an Overweight rating on Varun Beverages with a Rs 557 target, citing the company’s push into ready-to-drink and alcoholic beverages and its expansion in Tunisia.Nuvama has maintained a Hold on Cyient but raised its target to Rs 1,050 as margins improve, and the company

This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in GL.PR.D over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Accounting firm Deloitte agreed to pay $21.5 million to settle Department of Justice allegations that it violated the False Claims Act by failing to comply with anti-discrimination requirements in federal contracts and discriminating on the basis of race or sex, the department announced Tuesday.

The settlement resolves allegations that Deloitte violated the False Claims Act by failing to comply with anti-discrimination requirements in its federal contracts and allegedly discriminating against employees and applicants on the basis of their race or sex, according to the DOJ.

The DOJ said business units within Deloitte received monthly summaries tracking the “demographic goals” and alleged that the company’s partners, principals and managing directors were evaluated, in part, based on their contributions to helping it achieve its workforce composition goals.

TARGET PULLS ‘OFFENSIVE’ HALLOWEEN COSTUME CRITICS ACCUSED OF EVOKING BLACKFACE: ‘WE ARE DEEPLY SORRY’

Deloitte agreed to pay $21.5 million to settle a Department of Justice probe into the company’s diversity, equity and inclusion practices. (Jack Taylor/Getty Images / Getty Images)

The DEI goals, according to the DOJ, attempted to boost the representation of the Black and Hispanic communities in promotion decisions.

“Government contractors cannot reward or penalize employees based on race or sex — and labeling the practice DEI does not make it lawful,” Attorney General Todd Blanche said in a statement. “The Justice Department will aggressively pursue government contractors that have used taxpayer dollars to fund unlawful discrimination.”

Deloitte denies allegations of discriminatory conduct and said the settlement agreement does not represent an admission of liability. The company said it was pleased to resolve the matter to “avoid the cost and distraction of protracted litigation.”

The DOJ said the claims resolved in the settlement are allegations only and that there has been no determination of liability.

Deloitte denies allegations of discriminatory conduct and said the settlement agreement does not represent an admission of liability. (Photo by Artur Widak/NurPhoto via Getty Image / Getty Images)

The settlement also resolves claims brought under the False Claims Act’s qui tam provisions by the American Alliance for Equal Rights, a group founded by conservative activist and affirmative action opponent Edward Blum, which allows private parties, known as relators, to bring cases on the government’s behalf and potentially receive a share of any recovery.

Whistleblowers are entitled to a cut of any recovery in these cases. Blum’s group will receive $4.3 million as part of Tuesday’s agreement, the DOJ said.

“Merit drives opportunity and promotion. Not someone’s sex or race,” Associate Attorney General Stanley E. Woodward Jr. said in a statement. “Today’s settlement is yet another example of this Department’s commitment to eliminating woke, unconstitutional practices from American workplaces.”

WHITE HOUSE STUDY SAYS DEI POLICIES COST US ECONOMY BY PROMOTING UNQUALIFIED MANAGERS

Attorney General Todd Blanche said “labeling the practice DEI does not make it lawful.” (Alex Wroblewski / AFP via Getty Images / Getty Images)

CLICK HERE TO GET FOX BUSINESS ON THE GO

This comes as the Trump administration has sought to crack down on DEI initiatives since the president’s return to the White House. This has included executive orders aimed at rooting out DEI practices, such as orders directing federal contractors and subcontractors to certify that they do not operate DEI programs that violate applicable federal anti-discrimination laws.

The administration has targeted public ​and private organizations over DEI, including government agencies and universities. The administration has argued that some race and sex-conscious DEI programs are discriminatory and undermine merit-based decision-making.

Many U.S. companies scaled back ​or amended diversity policies in the wake of Trump’s crackdown.

A “social supermarket” offering low-cost food and support to escape financial hardship is to open at a third location in Kent.

SE Kitchen is due to open at the Pentagon Shopping Centre in Chatham in October, adding to branches in Ashford and Ramsgate.

The food shops, run by Social Enterprise Kent, redistribute surplus food and offer cut-price groceries.

The community interest company’s chief executive, Rebecca Smith, said: “We pride ourselves on creating a supportive, inclusive space where people can access what they need today while building a more stable, sustainable future.”

The Chatham shop will be open to all Medway residents with no referral or membership required, and will provide a community meeting space.

It will also offer “wrap-around support designed to address the root causes of financial hardship”, according to Medway Council.

Teresa Murray, the council’s deputy leader, said access to affordable and healthy food was “critically important” and a key factor in people’s well-being.

“Being able to put this new community supermarket in the heart of Chatham… is fantastic and will undoubtedly support the wider work we are undertaking,” she said.

Follow BBC Kent on Facebook, external, on X, external, and on Instagram, external and listen to BBC Radio Kent on Sounds. Send your story ideas to southeasttoday@bbc.co.uk, external or WhatsApp us on 08081 002250.

Clarke Willmott says the acquisition marks a ‘strategic milestone’ in its growth plans

A Southampton-headquartered law firm has acquired a specialist business immigration practice with offices in Manchester, London and Brussels for an undisclosed sum.

Clarke Willmott, which has a presence in Birmingham, Bristol, Manchester, London, Cardiff and Taunton, has agreed a deal for Latitude Law in move it says represents a “key strategic milestone”.

The acquisition brings a team of immigration specialists into the firm and creates a new dedicated UK immigration law capability for the business, Clarke Willmott said.

Latitude Law advises corporates, business owners and high-net-worth individuals on Home Office applications and compliance requirements. The firm is ranked in the Legal 500, Lexology and Chambers and Partners UK.

Peter Swinburn, Clarke Willmott chief executive, said: “We are delighted to announce our acquisition of Latitude Law and to welcome the team to the firm. They have an exceptional reputation in the market and are recognised for delivering first-class immigration advice to businesses and individuals alike.

“Just as importantly, they share our values and our commitment to building trusted, long-term relationships that deliver excellent outcomes for our clients, our people and the communities we serve. This acquisition represents an exciting step forward in our growth strategy and strengthens our ability to support clients with an increasingly important area of law.”

The new immigration team will be led by Gary McIndoe and will be based in Clarke Willmott’s Manchester office. It will become part of the commercial services division, headed by partner and the head of Manchester office Ed Foulkes.

The team is expected to complete its full integration into the firm in early November.

Mr McIndoe said: “When I started Latitude Law almost 20 years ago, I didn’t envisage it would grow into such a widely recognised specialist firm.

“I am extremely proud of the talented and dedicated team we have built, and of the strength of service we provide to clients across business and private wealth. Joining Clarke Willmott is an exciting and positive next step for us. We share culture, values and vision, and I’m confident that together we can offer our clients an even stronger service.”

Mr Foulkes added: “Latitude Law joining us is an exciting time for the firm and the Manchester office. The acquisition reinforces Clarke Willmott’s continued investment in strategic growth and its commitment to providing clients with a comprehensive range of specialist legal services across the UK.

“It’s a really positive development for the firm and another important milestone for the Manchester office.”